Balda AG: Balda AG and Mechatronic AG present joint development: App-controlled drug dispenser
12.10.2015
(DGAP-Media / 12.10.2015 / 11:14)
The Smart Drug Dispenser keeps track of tablets
Madrid, October 12, 2015 – Patients will soon be able to dose their drugs
via their smartphones. The medical technology companies Balda AG and
Mechatronic AG present the Smart Drug Dispenser exclusively within the
scope of the CPhI Worldwide in Madrid. The combination of app and
easy-to-handle drug dispenser helps prevent administration errors and thus
unnecessary complaints or hospital stays.
A signal helping patients: The Smart Drug Dispenser makes an important
contribution to the safety of the therapy. The physician or the patient may
conveniently enter the number and the time when the medication is to be
taken via the app. The device, which is about palm-sized, stores the dosage
regimen and dispenses the tablets via the push of a button. The associated
smartphone app reminds the user via text alerts and an acoustic signal that
the tablet may now be released from the device, until it has been
distributed. This prevents under or over dosage. The scientific figures
show that this support is dearly needed.
Forgotten, mistaken, lost – over 50 per cent of medication is not taken as
prescribed. According to studies, one in four patients does not follow the
therapy regimen. Not necessarily on purpose. Surveys show that many people
simply forget to take their drugs. Consequences such as extended healing
processes, secondary diseases and additional trips to the doctor are not
only bothersome for the patients. The costs to the German healthcare
systems due to deficient compliance are conservatively estimated to be in
excess of 10 billion EUR per year.
Christoph Klaus, Head of the Business Unit Balda Healthcare has recognized
the potential of the system: “An ageing population that is also tech-savvy
has a need for modern solutions. The Smart Drug Dispenser is an exciting
product that provides added value both for patients, physicians, relatives
and also health insurers”. Also Thomas Ullmann from Mechatronic AG is
pleased with the result of the cooperation of the development service
provider and the plastics specialist: “With the Smart Drug Dispenser, we
have taken an innovative step in the direction of user-friendly operation
whilst offering a high degree of user safety”.
Balda AG and Mechatronic AG will present their joint project between 13 and
15 October within the scope of the CPhI Worldwide in Madrid. Visitors may
test the Smart Drug Dispenser at booth 4B80 in hall 4.
Balda AG (ISIN: DE0005215107) is a provider of high-end plastics solutions
that rely on quality in sophisticated fields of application in the
healthcare, lifestyle, automotive and consumer electronics industry.
Balda operates in Europe and Northern America and has state of the art
production sites at the Oeynhausen headquarters in Germany and in the US.
The company’s success with its about 800 staff worldwide is based on the
use of modern, cost-efficient technologies and the close cooperation with
our customers in a spirit of trust.
Mechatronic AG is an international specialist in the development and
production of medical devices and the provision of services, software
products and test systems in the field of medical technology. Since 1987,
the company has been carrying out development and manufacturing work on
behalf of its customers, who can rely on its long-standing experience in
the industry and extensive expertise regarding processes and methods. Its
portfolio ranges from new developments and the redesign of existing
products and components to individual service modules.
Contact:
Balda AG
Kathrin Wiederrich
Bergkirchener Str. 229
32549 Bad Oeynhausen
Tel: +49 5734 922 2023
Mobil: +49 176 19227157
Mail: kwiederrich@balda-group.com
Mechatronic AG
Ricarda Groß
Wittichstr. 2
64295 Darmstadt
+49 6151 5003 172
Mail: ricarda.gross@mechatronic.de
Source:
www.kohlpharma.com/_data/mediapool/banner/1185522850_2_Pressemitte
ilung_Wille.pdf
DiMatteo, M. R., Variations in patients adherence to medical
recommendations: a quantitative review of 50 years of research. Med. Care
42 (2004) 200-209.
www.pharmazeutische-zeitung.de/index.php
gesundheitsmonitor.de/schwerpunkte/versorgungserfahrung/detail/stud
ien/zeige/non-compliance-bei-der-arzneimitteltherapie-umfang-hintergruende
-veraenderungswege/
deutschesapothekenportal.de/compliance.html
Michaela Gräf: Die volkswirtschaftlichen Kosten der Non-Compliance: Eine
entscheidungsorientierte Analyse. P.C.O.-Verlag; edition: 1st, ed. (August
13, 2007)
apothekengefluester.de/oekonomische-und-klinische-konsequenzen-durc
h-non-compliance/
End of Media Release
———————————————————————
Issuer: Balda AG
Key word(s): Industry
12.10.2015 Dissemination of a Press Release, transmitted by DGAP – a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
———————————————————————
Language: English
Company: Balda AG
Bergkirchener Str. 228
32549 Bad Oeynhausen
Germany
Phone: +49 (0) 57 34 / 9 22-0
Fax: +49 (0) 57 34 / 9 22-2604
E-mail: ir@balda-group.com
Internet: www.balda-group.com
ISIN: DE0005215107
WKN: 521510
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart
End of News DGAP Media
———————————————————————
401787 12.10.2015